Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | ITGAL | P20701 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948201 | 1.00 | SSTR4 (0.41) | SSTR4ITGB2ICAM1ITGALPTGDR2 | |
| SCHEMBL30207743 | 1.00 | SSTR4 (0.41) | SSTR4ITGB2ICAM1ITGALPTGDR2 | |
| SCHEMBL769058 | 1.00 | SSTR4 (0.41) | SSTR4ITGB2ICAM1ITGALPTGDR2 | |
| SCHEMBL5847641 | 1.00 | SSTR4 (0.41) | SSTR4ITGB2ICAM1ITGALPTGDR2 | |
| SCHEMBL27833998 | 0.98 | SSTR4 (0.40) | SSTR4ITGB2ICAM1ITGALPTGDR2 | |
| Hydrochloric Acid SCHEMBL28001542 | 0.98 | SSTR4 (0.40) | SSTR4ITGB2ICAM1ITGALPTGDR2 | |
| Cyanate SCHEMBL27883107 | 0.92 | PTGDR2 (0.41) | PTGDR2 | |
| SCHEMBL7420482 | 0.90 | NPC1 (0.40) | SSTR4ITGB2ICAM1ITGALALDH1A1 | |
| SCHEMBL27675759 | 0.86 | PTGDR2 (0.42) | SSTR4PTGDR2SMN1; SMN2 | |
| SCHEMBL24075070 | 0.84 | SSTR4 (0.40) | SSTR4ITGB2ICAM1ITGALGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897842-B1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2025-01-29 | — | — | EP | disclosed |
| CN-113490527-B | Bicyclic derivatives | 瑞士伊兰科动物保健有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| CN-115667221-A | Substituted fused oxazines as insect repellent compounds | 拜耳动物保健有限责任公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220064159-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-03 | — | — | US | disclosed |
| EP-3902798-A1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | Endogena Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3897842-A1 | BICYCLIC DERIVATIVES | Elanco Tiergesundheit AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113490527-A | Bicyclic derivatives | 瑞士伊兰科动物保健有限公司 | 2021-10-08 | — | — | CN | disclosed |
| WO-2020140050-A1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020131631-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-7034051-B2 | Fused bicyclic carboxamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| WO-2005023799-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064159-A1 | BICYCLIC DERIVATIVES | FABP3, CYCS, PIGS | SSTR4 3439/4885ITGB2 772/4885ICAM1 1769/4885 |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 | SSTR4 2481/4885ITGB2 3950/4885ICAM1 4873/4885 |
| US-20230174492-A1 | SUBSTITUTED CONDENSED AZINES AS ANTHELMINTIC COMPOUNDS | H1-5, H1-10, H1-0 | SSTR4 3943/4885ITGB2 3022/4885ICAM1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.